{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:48:27Z","timestamp":1779122907265,"version":"3.51.4"},"reference-count":12,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2007]]},"abstract":"<i>Background and Aims:<\/i> Patients with esophageal cancer often develop metastatic disease after esophageal resection and generally receive cisplatin-based chemotherapy or chemoradiotherapy. The efficacy and toxicity of the combination of docetaxel, 5-fluorouracil (5-FU) and cisplatin (DFC) as a second-line chemotherapy were evaluated in patients with postoperative metastatic esophageal cancer refractory to cisplatin-based chemotherapy. <i>Patients and Methods:<\/i> Twenty patients with metastatic esophageal cancer after esophagectomy refractory to cispatin-based therapy were included in this study. The DFC regimen consisted of docetaxel (60 mg\/m<sup>2<\/sup>) on day 1, 5-FU (500 mg\/day) on days 1\u20135 and cisplatin (10 mg\/day) on days 1\u20135, being repeated every 3 weeks. <i>Results:<\/i> A total of 49 cycles (median 2, range 1\u20136) was administered to 20 patients. The median follow-up was 8 months (range 3\u201324). Of the 20 patients, 1 had a complete response, 6 had a partial response, 6 had stable and 7 had progressive disease. Median time to progression for all patients was 4 months (95% Cl 1.7\u20135.6). The median overall survival for all patients was 8 months (95% CI 5.7\u201310.3). The major toxicity was myelosuppression. Neutropenia of grade 3 or more occurred in 13 patients (65%), and thrombocytopenia of grade 3 occurred in 1 patient (5%). Febrile neuropenia was observed in 1 patient (5%). There was no treatment-related mortality. <i>Conclusion:<\/i> DFC is a feasible and promising regimen as a second-line therapy in metastatic\/recurrent esophageal cancer refractory to cisplatin-based chemotherapy.<\/jats:p>","DOI":"10.1159\/000110018","type":"journal-article","created":{"date-parts":[[2007,10,19]],"date-time":"2007-10-19T11:00:58Z","timestamp":1192791658000},"page":"449-453","source":"Crossref","is-referenced-by-count":20,"title":["Second-Line Combination Chemotherapy with Docetaxel for Cisplatin-Pretreated Refractory Metastatic Esophageal Cancer: A Preliminary Report of Initial Experience"],"prefix":"10.1159","volume":"53","author":[{"given":"Toshiaki","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromasa","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Sueyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Sasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Yamana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Shirouzu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2007,10,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00268-003-6913-z"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2FS0959-8049%2897%2900088-9"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093%2Fjjco%2Fhye090"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038%2Fsj.bjc.6600166"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159%2F000089102"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093%2Fjnci%2F92.3.205"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016%2FS1470-2045%2805%2970094-2"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159%2F000085619"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159%2F000094869"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093%2Fannonc%2Fmdh231"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038%2Fsj.bjc.6601168"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2005.17.376"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/110018","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/110018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T02:00:29Z","timestamp":1745460029000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000110018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"references-count":12,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2007,11,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000110018","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"value":"0009-3157","type":"print"},{"value":"1421-9794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007]]}}}